English Spanish Chinese Russian German French Japanese Hindi Telugu Tamil

Arquivos de Medicina

  • ISSN: 1989-5216
  • Índice h do diário: 22
  • Pontuação de citação de diário: 4.96
  • Fator de impacto do periódico: 4.44
Indexado em
  • Genamics JournalSeek
  • Infraestrutura Nacional de Conhecimento da China (CNKI)
  • Diretório de Indexação de Periódicos de Pesquisa (DRJI)
  • OCLC- WorldCat
  • Invocação Proquest
  • publons
  • Fundação de Genebra para Educação e Pesquisa Médica
  • Euro Pub
  • Google Scholar
  • Laboratórios secretos do mecanismo de pesquisa
Veja mais
Compartilhe esta página

Abstrato

Benefits and Limits of Risperidone-Methylphenidate Combination in Child Psychiatry: 3 Cases

Hervé Javelot, Bruno Michel, Nicolas Didelot, Luisa Weiner, Claire Glay-Ribau, Bernard Kabuth

Methylphenidate remains the first choice treatment for attention deficit hyperactivity disorder (ADHD), but comorbid forms with Disruptive Behaviour Disorders (DBD) are undertreated.

Methylphenidate adjunction is sometimes necessary in order to treat ADHD-related symptoms in DBD behaviors initially well-regulated with risperidone. In these situations, psychostimulant-antipsychotic combinations can be a useful strategy.

We report three cases of methylphenidate-risperidone combination in the context of our clinical experience with this bitherapy.

The cases show potential benefits to treat comorbid- ADHD with DBD with the psychostimulant-antipsychotic combination and the limits due to the risk of dyskinesia.